Senator Jim Banks Sends Letter to Acting FDA Commissioner Regarding Dangerous Counterfeit Weight Loss DrugsThursday, April 3, 2025

WASHINGTON, D.C.– Yesterday, Senator Jim Banks (R-Ind.) sent a letter to Dr. Sara Brenner, Acting Commissioner of Food and Drugs, regarding unregulated and potentially dangerous active pharmaceutical ingredients (APIs) being shipped to the US from foreign countries and used in injectable weight loss drugs.
In part, the letter reads:
“I request detailed information about how the Food and Drug Administration (FDA) will prevent unlawful APIs from entering the country and potentially harming Americans.
As of December 31, 2024, the FDA’s Adverse Event Reporting System database lists more than 900 cases of adverse health events associated with compounded “semaglutide” and “tirzepatide,” of which 17 involved deaths. These adverse events represent more thanquadruplethe number of adverse events recorded forallcompounded drugs in FY 2022.”
Clickhereto see the full letter or see text below:
Dear Dr. Brenner:
I write to share my deep concern about the use of foreign-made active pharmaceutical ingredients (APIs) in compounded glucagon-like peptide 1 (GLP-1) agonist medications (injectable weight-loss drugs) used by millions of American patients. Booming online gray and black markets are flooding the country with knock-off and counterfeit GLP-1s contaminated with foreign-made APIs, and few Americans purchasing these drugs are aware of the risks they pose. I request detailed information about how the Food and Drug Administration (FDA) will prevent unlawful APIs from entering the country and potentially harming Americans.
As of December 31, 2024, the FDA’s Adverse Event Reporting System database lists more than 900 cases of adverse health events associated with compounded “semaglutide” and “tirzepatide,” of which 17 involved deaths. These adverse events represent more thanquadruplethe number of adverse events recorded forallcompounded drugs in FY 2022.
Even after the FDA declared the end of the tirzepatide medication shortage on October 2, 2024 and the end of the semaglutide medication shortage on February 21, 2025, and the judge’s March 5, 2025 denial of an injunction in Outsourcing Facilities Association v. FDA—which upheld the FDA’s declaration and confirmed that compounding pharmacies must cease making such knock-off drugs—these drugs remain readily available. Many patients using such knock-off medications are unaware they are inauthentic, lack FDA approval, and may be adulterated or non-sterile. This marketplace has become deceptive, and many patients are unaware of the risks they are taking.
I share the state attorneys general’s alarm about the proliferation of injectable weight-loss drugs compounded using tainted APIs imported from China, India, and other countries. These drugs come in formulations that the FDA has never approved, have inconsistent doses, misrepresent injectable insulin as semaglutide, contain contaminants, or are in reality completely different drugs. Unscrupulous compounders and merchants selling these drugs must be shut down.
Under federal law, compounders can only use APIs that are accompanied by a valid certificate of analysis (COA) and manufactured at a facility registered with the FDA. However, there is no evidence that the FDA is assessing at the border (or anywhere else) whether imported APIs come from duly registered sources, whether these shipments have COAs, whether the COAs are valid, or whether the COAs demonstrate acceptable quality testing. The FDA has issued very few warning letters to compounders for breaking these rules, and the agency rarely seems to be checking the validity of COAs during inspections of compounding facilities.
As a result of lax oversight, the FDA is allowing in mass amounts of APIs that were manufactured at unregistered foreign plants and should not be allowed entry into the U.S. This is particularly a problem in China, where companies that export APIs are not even required to hold drug manufacturing licenses or meet safety requirements that apply to medicines sold within China.
I encourage the FDA to fully enforce the Federal Food, Drug, and Cosmetic Act and close the loopholes that unscrupulous compounders, telehealth providers, and merchants continue to exploit. I also urge the FDA to increase inspections and work more closely with Customs and Border Protection to intercept illicit bulk drug ingredients and shut down unregistered compounders.
I respectfully ask that you provide answers to the following questions by no later than April 25, 2025:
Thank you for your attention to this important matter.
Read more about the letterhere.